Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients
1997

Monoclonal Antibodies E48 and U36 for Head and Neck Cancer Treatment

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): R de Bree, JC Roos, MABD Plaizier, JJ Quak, GJ van Kamp, W den Hollander, GB Snow, GAMS van Dongen

Primary Institution: Free University Hospital, Amsterdam, The Netherlands

Hypothesis

Can monoclonal antibodies E48 and U36 be effectively used for adjuvant radioimmunotherapy in head and neck cancer patients?

Conclusion

Both monoclonal antibodies E48 and U36 show high selective uptake in head and neck cancer, with U36 demonstrating a more homogeneous distribution at higher doses.

Supporting Evidence

  • Both mE48 IgG and mU36 IgG showed high uptake in tumor tissue.
  • U36 demonstrated a more homogeneous distribution at higher doses compared to E48.
  • 12 out of 28 patients developed a human anti-mouse antibody response to mE48 IgG.
  • mU36 IgG was less immunogenic than mE48 IgG.
  • Statistical analysis showed no significant differences in tumor uptake between the two antibodies.

Takeaway

Doctors are testing two special proteins to help treat throat and mouth cancer, and one of them works better at spreading evenly in the cancer.

Methodology

Ten patients received both mE48 IgG and mU36 IgG simultaneously, and their biodistribution was assessed through imaging and biopsies.

Potential Biases

Potential bias in patient selection and variability in individual responses to treatment.

Limitations

The study had a small sample size and variability in antibody uptake among patients.

Participant Demographics

Patients with head and neck squamous cell carcinoma, varying in age and sex.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication